▼ -3.48% Downside Potential
This price target is based on 10 analysts offering 12 month price targets for Kura Oncology in the last 3 months. The average price target is $34.33, with a high forecast of $43.00 and a low forecast of $24.00. The average price target represents a -3.48% upside from the last price of $35.57.
The current consensus among 10 contributing investment analysts is to buy stock in Kura Oncology. This Buy consensus rating has held steady for over two years.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, and other hematologic malignancies. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have dysregulated activity due to mutations or other mechanisms in the mitogen-activated protein kinase pathway; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia protein-protein interaction. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.